TheEdgeResearch
Home / Stocks / CELZ

Creative Medical Technology Holdings, Inc. (CELZ)

NASDAQ Healthcare Biotechnology
$1.18 ▼ -4.84%
Market Cap
$3.0M
Sector
Healthcare
Industry
Biotechnology
Beta
1.88
52-Wk Range
0.62-6.25
CEO
Timothy Warbington
Country
US
Currency
USD

Creative Medical Technology Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Phoenix, AZ, US. The stock last traded at $1.18, down 4.84% on the session, giving a market capitalisation of $3.0M. On trailing twelve-month figures it carries a trailing P/E of -0.59, a net margin of -201355.4%. Its beta of 1.88 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.59
Price / Sales
1015.06
Price / Book
0.50
EV / EBITDA
1.25
Gross margin
-968.4%
Operating margin
-155932.3%
Net margin
-201355.4%
Return on equity
Debt / equity
0.00
Current ratio
12.91
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
4
IPO date
2015-11-06
Headquarters
Phoenix, AZ, US
About Creative Medical Technology Holdings, Inc.

Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.

Comparable companies

Creative Medical Technology Holdings, Inc. is most often compared with the following Healthcare names:

ACXPADILADXNALZNAPREBCDACDIOHCWBKPRXPHIO
More research on CELZ
CELZ technical analysis CELZ TheEdge Score Compare against peers
Open full interactive analysis & DCF →